HK1137753A1 - Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists - Google Patents

Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists

Info

Publication number
HK1137753A1
HK1137753A1 HK10102651.4A HK10102651A HK1137753A1 HK 1137753 A1 HK1137753 A1 HK 1137753A1 HK 10102651 A HK10102651 A HK 10102651A HK 1137753 A1 HK1137753 A1 HK 1137753A1
Authority
HK
Hong Kong
Prior art keywords
pyrido
pyrimidin
derivatives
receptor antagonists
calcium receptor
Prior art date
Application number
HK10102651.4A
Other languages
English (en)
Inventor
Feng Bi
Mary Theresa Didiuk
David Andrew Griffith
Angel Guzman-Perez
Kevin Kun-Chin Liu
Daniel Patrick Walker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HK1137753A1 publication Critical patent/HK1137753A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK10102651.4A 2006-10-04 2010-03-15 Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists HK1137753A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82816206P 2006-10-04 2006-10-04
US96908307P 2007-08-30 2007-08-30
PCT/IB2007/002976 WO2008041118A2 (fr) 2006-10-04 2007-09-26 Dérivés de pyrido[4,3-d]pyrimidin-4(3h)-one utilisés en tant qu'antagonistes du récepteur calcique

Publications (1)

Publication Number Publication Date
HK1137753A1 true HK1137753A1 (en) 2010-08-06

Family

ID=39183043

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10102651.4A HK1137753A1 (en) 2006-10-04 2010-03-15 Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists

Country Status (17)

Country Link
US (2) US7829572B2 (fr)
EP (1) EP2079739A2 (fr)
JP (1) JP2010505811A (fr)
KR (1) KR101129868B1 (fr)
CN (1) CN101547922B (fr)
AR (1) AR063122A1 (fr)
AU (1) AU2007303846B2 (fr)
CA (1) CA2663436A1 (fr)
CL (1) CL2007002864A1 (fr)
HK (1) HK1137753A1 (fr)
IL (1) IL197536A0 (fr)
MX (1) MX2009003673A (fr)
NO (1) NO20091328L (fr)
PE (1) PE20081455A1 (fr)
TW (1) TW200822929A (fr)
UY (1) UY30620A1 (fr)
WO (1) WO2008041118A2 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8845672B2 (en) 2002-05-09 2014-09-30 Reshape Medical, Inc. Balloon system and methods for treating obesity
US20070100368A1 (en) 2005-10-31 2007-05-03 Quijano Rodolfo C Intragastric space filler
US8226602B2 (en) * 2007-03-30 2012-07-24 Reshape Medical, Inc. Intragastric balloon system and therapeutic processes and products
US8142469B2 (en) 2007-06-25 2012-03-27 Reshape Medical, Inc. Gastric space filler device, delivery system, and related methods
US9174031B2 (en) * 2009-03-13 2015-11-03 Reshape Medical, Inc. Device and method for deflation and removal of implantable and inflatable devices
EP2414025A4 (fr) * 2009-04-03 2017-08-02 ReShape Medical, Inc. Charges améliorées de l'espace intragastrique et procédés de préparation, comprenant des tests in vitro
CN101619063B (zh) * 2009-06-02 2011-08-10 华中师范大学 具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-d]嘧啶衍生物及制备
WO2011011629A2 (fr) 2009-07-22 2011-01-27 Reshape Medical, Inc. Mécanismes de retrait pour dispositifs médicaux implantables
EP2456505B1 (fr) 2009-07-23 2017-05-24 ReShape Medical, Inc. Dégonflage et retrait de dispositif médicaux implantables
US9604038B2 (en) 2009-07-23 2017-03-28 Reshape Medical, Inc. Inflation and deflation mechanisms for inflatable medical devices
WO2011097637A1 (fr) 2010-02-08 2011-08-11 Reshape Medical, Inc. Matériaux et procédés pour dispositifs améliorés à ballon intragastrique
EP2533845A4 (fr) 2010-02-08 2016-04-06 Reshape Medical Inc Procédés et mécanismes d'aspiration améliorés et perfectionnés pour dispositifs intragastriques
US9681973B2 (en) 2010-02-25 2017-06-20 Reshape Medical, Inc. Enhanced explant processes and mechanisms for intragastric devices
EP2555705A4 (fr) 2010-04-06 2014-01-15 Reshape Medical Inc Dispositifs de gonflage pour des dispositifs intragastriques à une fixation et un détachement améliorés et systèmes et procédés associés
BR112013001634A2 (pt) 2010-07-23 2016-05-24 Takeda Pharmaceutical composto ou sal, medicamento, métodos para a profilaxia ou tratamento da arteriosclerose, da diabete ou obesidade em um mamífero, e, uso do composto ou sal
EP2413139B1 (fr) 2010-07-30 2015-05-20 Universität Leipzig Procédé et compositions pour l'identification d'agents qui ont un effet potentiel contre les maladies inflammatoires chroniques
CA2828415A1 (fr) 2011-03-10 2012-09-13 Lupin Limited Morpholines substituees en tant que modulateurs pour le recepteur de calcium
WO2012127385A1 (fr) 2011-03-18 2012-09-27 Lupin Limited Dérivés benzo[b][1,4]oxazine en tant que modulateurs de récepteurs de détection de calcium
AP2014007805A0 (en) 2011-12-28 2014-07-31 Cytokinetics Inc The Regents Of The University Of California Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
CA2864332C (fr) 2012-02-24 2020-08-25 Lupin Limited Composes substitues de chromane en tant que modulateurs des recepteurs de detection du calcium
WO2013136288A1 (fr) 2012-03-16 2013-09-19 Lupin Limited Composés de type 3,4-dihydro-2h-benzo[b] [1,4]oxazine substituée utilisés en tant que modulateurs des récepteurs sensibles au calcium
WO2014033604A1 (fr) 2012-08-27 2014-03-06 Lupin Limited Composés d'arylalkylamine jouant le rôle de modulateurs des récepteurs sensibles au calcium
ES2864707T3 (es) 2013-03-15 2021-10-14 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EA034922B1 (ru) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
ES2890077T3 (es) 2013-03-15 2022-01-17 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ITTO20130430A1 (it) * 2013-05-28 2014-11-29 Illinois Tool Works Dispositivo per il pre-riscaldamento ad induzione e la saldatura testa a testa di lembi adiacenti di almeno un elemento da saldare
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
AU2014313835A1 (en) 2013-08-28 2016-03-03 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
BR112015032160B1 (pt) 2014-02-07 2021-11-30 Global Blood Therapeutics, Inc Ansolvato cristalino de composto, composição e composição farmacêutica
WO2015162538A1 (fr) 2014-04-21 2015-10-29 Lupin Limited Composés hétérocycliques en tant que modulateurs des récepteurs de détection du calcium pour le traitement de l'hyperparathyroïdie, de l'insuffisance rénale chronique et de la néphropathie chronique
US11172549B2 (en) * 2014-10-14 2021-11-09 Illinois Tool Works Inc. High-productivity hybrid induction heating/welding assembly
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
WO2017037616A1 (fr) 2015-08-31 2017-03-09 Lupin Limited Composés d'arylalkylamine comme modulateurs des récepteurs sensibles au calcium
TW201731509A (zh) 2015-12-04 2017-09-16 全球血液治療公司 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CN108164455A (zh) * 2017-03-23 2018-06-15 广东众生药业股份有限公司 马来酸非尼拉敏的合成方法
CN107903209B (zh) * 2017-12-29 2021-05-14 宁夏忠同生物科技有限公司 一种2-氨基-5-氟吡啶-3-甲酸甲酯的合成方法
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
KR102338609B1 (ko) * 2019-05-20 2021-12-14 보령제약 주식회사 피리도-피리미딘 화합물 및 이를 유효성분으로 포함하는 pi3k 관련 질환의 예방 또는 치료용 약학적 조성물
JP2023512754A (ja) 2019-12-27 2023-03-29 ルピン・リミテッド ＣａＳＲモジュレーターの医薬組成物ならびにその方法および使用
US20230140054A1 (en) 2020-01-17 2023-05-04 Lupin Limited Methods, processes and intermediates for preparing chroman compounds
CN113956268B (zh) * 2021-11-19 2022-07-15 西安欧得光电材料有限公司 一种6-溴-1-氯苯并噻吩[2,3-c]吡啶及合成方法

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US646572A (en) * 1899-03-15 1900-04-03 Archibald C Floyd Bath-cabinet.
CH624395A5 (fr) * 1976-01-08 1981-07-31 Ciba Geigy Ag
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
EP0054132B1 (fr) * 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Pyrimidones, leur préparation et médicaments les contenant
US4422711A (en) 1981-12-21 1983-12-27 Amp Incorporated Active pin contact
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
US4588812A (en) * 1984-05-30 1986-05-13 Pennwalt Corporation Substituted 2,3-dihydro-5H-thiazolo[2,3,-b]quinazoline derivatives
GB8429739D0 (en) * 1984-11-24 1985-01-03 Fbc Ltd Fungicides
GB8513754D0 (en) 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
GB8811435D0 (en) * 1988-05-13 1988-06-15 Ici Plc Fungicides
DE68905765T3 (de) 1988-11-21 1998-03-26 Zeneca Ltd Fungizide.
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
IE62559B1 (en) * 1989-02-02 1995-02-08 Ici Plc Fungicides
US5145856A (en) 1989-02-10 1992-09-08 Imperial Chemical Industries Plc Fungicides
BE1003002A6 (fr) 1989-03-21 1991-10-22 Coppe Jan Composition a mettre en oeuvre pour le traitement de la calvitie, et procedes faisant usage de celle-ci.
GB8914797D0 (en) * 1989-06-28 1989-08-16 Ici Plc Fungicides
US5240928A (en) 1989-07-03 1993-08-31 Merck & Co., Inc. Substituted quinazolinones as angiotensin II antagonists
US5187779A (en) * 1989-08-11 1993-02-16 Micral, Inc. Memory controller with synchronous processor bus and asynchronous i/o bus interfaces
GB9016783D0 (en) 1989-09-01 1990-09-12 Ici Plc Agrochemical compositions
GB8928547D0 (en) * 1989-12-18 1990-02-21 Ici Plc Fungicides
AU6812790A (en) 1989-12-22 1991-06-27 Ici Americas Inc. Fungicidal compounds
GB9000130D0 (en) * 1990-01-04 1990-03-07 Ici Plc Fungicides
US5264439A (en) 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
CA2037630C (fr) * 1990-03-07 2001-07-03 Akira Morimoto Composes heterocycliques renfermant de l'azote, methode de production et applications correspondantes
GB9012017D0 (en) * 1990-05-30 1990-07-18 Ici Plc Fungicidal compounds
GB9013615D0 (en) 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
US5225318A (en) * 1990-07-02 1993-07-06 Ocg Microelectronic Materials, Inc. Selected photoactive methylolated cyclohexanol compounds and their use in forming positive resist image patterns
GB9016584D0 (en) * 1990-07-27 1990-09-12 Ici Plc Fungicides
GB9016578D0 (en) 1990-07-27 1990-09-12 Ici Plc Fungicides
MY107955A (en) * 1990-07-27 1996-07-15 Ici Plc Fungicides.
GB9018408D0 (en) 1990-08-22 1990-10-03 Ici Plc Fungicides
US5110471A (en) * 1990-08-30 1992-05-05 Conoco Specialty Products Inc. High efficiency liquid/liquid hydrocyclone
GB9023294D0 (en) 1990-10-25 1990-12-05 Ici Plc Fungicides
US5290780A (en) * 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
NZ242290A (en) 1991-04-15 1994-12-22 Zeneca Ltd Pyridyl and pyrimidinyl substituted oxime-o-benzyl ether derivatives; preparatory processes, fungicidal compositions and an intermediate
US5252574A (en) 1991-04-26 1993-10-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
US5162325A (en) 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
CA2102780C (fr) * 1991-05-10 2007-01-09 Alfred P. Spada Composes de type bis-monoaryle, aryle bicyclique et (ou) heteroaryle inhibant l'activite de tyrosine kinase des recepteurs de l'egf et (ou) du pdgf
US5158953A (en) 1991-08-13 1992-10-27 National Science Council 2-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (thiones), the preparation and use thereof
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
DE4130298A1 (de) 1991-09-12 1993-03-18 Basf Ag Fungizide mischungen
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
DE4243340A1 (de) * 1992-12-21 1994-06-23 Sued Chemie Ag Sorptionsmittel
US5420133A (en) * 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
ATE136734T1 (de) 1993-09-24 1996-05-15 Basf Ag Fungizide mischungen
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
JP3364727B2 (ja) * 1993-10-22 2003-01-08 イハラケミカル工業株式会社 ２，２−ビス（３，５−ジ置換−４−ヒドロキシフェニル）プロパン誘導体とその製造方法およびこの誘導体を用いるピロガロールの製造法
US5464854A (en) * 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
EP1203761B1 (fr) * 1994-10-21 2005-01-19 Nps Pharmaceuticals, Inc. Composés capables de moduler l'activité du récepteur de calcium
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19501481A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
DE122005000053I2 (de) 1995-03-30 2008-01-17 Pfizer Prod Inc Chinazolinderivate
MY115814A (en) 1995-06-16 2003-09-30 Bayer Ip Gmbh Crop protection compositions
WO1997006678A1 (fr) 1995-08-17 1997-02-27 Basf Aktiengesellschaft Melanges fongicides
US6897213B1 (en) 1995-11-21 2005-05-24 Warner-Lambert Company Heterocycles as cholecystokinin (CCK) ligands
JPH09241110A (ja) * 1996-03-08 1997-09-16 Sumitomo Chem Co Ltd 殺菌剤組成物
JP2000509054A (ja) * 1996-04-26 2000-07-18 ビーエーエスエフ アクチェンゲゼルシャフト 殺菌剤混合物
BR9708873B1 (pt) * 1996-04-26 2009-05-05 mistura fungicida, e, processo para controlar fungos nocivos.
EP0901487B9 (fr) 1996-05-15 2004-09-29 Pfizer Inc. 4(3h)-quinazolinones trisubstituees en position 2,3 et 6
ID19609A (id) * 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
DE19629825A1 (de) 1996-07-24 1998-01-29 Bayer Ag Dihydrofuran-carboxamide
CA2265495A1 (fr) 1996-09-13 1998-03-19 The Board Of Trustees Of The Leland Stanford Junior University Methode contraceptive non hormonale
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
EA001963B1 (ru) 1997-02-28 2001-10-22 Пфайзер Продактс Инк. Атропизомеры 3-арил-4(3н)-хиназолинонов и их использование в качестве антагонистов амра-рецепторов
ID23435A (id) * 1997-02-28 2000-04-20 Pfizer Prod Inc Atropisomer dari 3-heteroaril-4(3h)-kuinazolinon untuk pengobatan neurodegeratif dan kondisi-kondisi yang terkait dengan trauma-cns
US5948775A (en) * 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
FR2762841B1 (fr) * 1997-04-30 1999-07-02 Jouveinal Inst Rech Diazepino-indolones inhibitrices de phosphodiesterases iv
CO5050364A1 (es) 1997-05-28 2001-06-27 Basf Ag Metodo para controlar hongos nocivos
AU749368B2 (en) * 1997-06-04 2002-06-27 Basf Aktiengesellschaft Fungicidal mixture
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US5753851A (en) * 1997-06-16 1998-05-19 The United States Of America As Represented By The Secretary Of The Army Spinning mine with concentrated projectiles
EP0900567A3 (fr) 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-ones antagonistes d'AMPA pour le traitement des dyscinésies associées à la thérapie aux agonistes de la dopamine
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
TW431861B (en) * 1997-12-18 2001-05-01 Basf Ag Fungicidal mixtures based on amide compounds and azoles
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
PL342243A1 (en) * 1998-01-27 2001-06-04 Aventis Pharm Prod Inc Substituted oxoazaheterocyclic inhibitors of the factor xa
JPH11279158A (ja) 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
JPH11228643A (ja) * 1998-02-17 1999-08-24 Menicon Co Ltd 眼用レンズ材料およびその製法
WO1999044612A1 (fr) 1998-03-02 1999-09-10 Cocensys, Inc. Quinazolines substituees, leurs analogues, et leur utilisation
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
US6187779B1 (en) * 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
GB9828340D0 (en) 1998-12-22 1999-02-17 Novartis Ag Organic compounds
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
FR2792938B1 (fr) 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
JP4831906B2 (ja) * 1999-08-27 2011-12-07 ケモセントリックス， インコーポレイテッド Ｃｘｃｒ３機能を調節するための複素環式化合物および方法
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US7060706B1 (en) * 1999-09-28 2006-06-13 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6562830B1 (en) * 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6664390B2 (en) 2000-02-02 2003-12-16 Warner-Lambert Company Llc Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
US6697213B2 (en) * 2000-03-31 2004-02-24 Seagate Technology Llc Cover including multiple cover plates with damped layers
MXPA02010322A (es) 2000-04-19 2004-09-10 Univ Johns Hopkins Metodos para la prevencion y tratamiento de trastornos gastrointestinales.
ES2527754T3 (es) * 2000-04-25 2015-01-29 Icos Corporation Inhibidores de la isoforma delta de la fosfatidilinositol 3-quinasa humana
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
DE60136187D1 (de) * 2000-08-11 2008-11-27 Japan Tobacco Inc Calciumrezeptor-antagonisten
EP1188438A1 (fr) 2000-09-15 2002-03-20 Warner-Lambert Company Compositions pharmaceutiques pour la prévention ou le traitement de maladies associées à un excès de production de l' IL-12
JP2004509876A (ja) * 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４−アミノ−キナゾリン
EP1326863A2 (fr) * 2000-09-22 2003-07-16 Ortho-McNeil Pharmaceutical, Inc. Octahydro-indolizines et quinolizines et hexahydro-pyrrolizines
EP1331950B1 (fr) * 2000-10-13 2009-10-14 The Johns Hopkins University Procedes ex vivo et compositions permettant la diffusion d'acide nucleique
EP1404654A4 (fr) * 2000-10-25 2008-12-03 Smithkline Beecham Corp Composes calcilytiques
JP4259877B2 (ja) 2000-12-11 2009-04-30 アムジエン・インコーポレーテツド Ｃｘｃｒ３アンタゴニスト
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
HUP0303249A3 (en) 2001-02-22 2007-03-28 Sankyo Co Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them
JPWO2002094790A1 (ja) 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
EP1392684B1 (fr) * 2001-06-01 2006-09-13 Vertex Pharmaceuticals Incorporated Composes de thiazole inhibiteurs des proteines kinases
US7220777B2 (en) * 2001-10-15 2007-05-22 Smithkline Beecham P.L.C. Lactam derivatives as antagonists for human 11cby receptors
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
US20040110777A1 (en) * 2001-12-03 2004-06-10 Annis Gary David Quinazolinones and pyridinylpyrimidinones for controlling invertebrate pests
EP1471910A2 (fr) * 2002-01-17 2004-11-03 Neurogen Corporation Analogues de quinazoline-4-ylamine substitues comme modulateurs de receptors de la capsaicin
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
WO2003070701A2 (fr) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses de quinazolinones
AU2003229724B2 (en) 2002-04-26 2009-07-02 Altana Pharma Ag Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
RU2004135386A (ru) 2002-05-06 2005-07-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Тиадиазолы или оксадиазолы и их применение в качестве ингибиторов протеинкиназы jak
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
JP2006506401A (ja) * 2002-05-23 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
JP2005536475A (ja) * 2002-05-23 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
PT1551834E (pt) * 2002-05-23 2010-09-30 Novartis Vaccines & Diagnostic Compostos de quinazolinona substituídos
WO2004009036A2 (fr) * 2002-07-23 2004-01-29 Cytokinetics, Inc. Composes, compositions et procedes
US20040048853A1 (en) 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
US20040242572A1 (en) 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
EP1558083A4 (fr) 2002-09-30 2008-04-16 Cytokinetics Inc Composes, compositions, et procedes
KR20110050745A (ko) 2002-10-03 2011-05-16 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
GB0223730D0 (en) * 2002-10-11 2002-11-20 Novartis Ag Organic compounds
EP1553947A4 (fr) * 2002-10-21 2006-11-29 Bristol Myers Squibb Co Quinazolinones et derives de celles-ci comme inhibiteurs du facteur xa
AU2003291761A1 (en) * 2002-11-04 2004-06-07 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
FR2846657B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20040142958A1 (en) * 2002-12-13 2004-07-22 Neurogen Corporation Combination therapy for the treatment of pain
GB0230015D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds
AU2004212421B2 (en) 2003-02-07 2009-08-20 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
ATE398125T1 (de) 2003-03-12 2008-07-15 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
US7488757B2 (en) * 2003-03-24 2009-02-10 Becton, Dickinson And Company Invisible antimicrobial glove and hand antiseptic
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
EP1614676A4 (fr) 2003-03-27 2009-03-25 Kirin Pharma Kk Compose inhibiteur in vivo de transport de phosphore et medicament en contenant
EP2258365B1 (fr) * 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Utilisation de composés organiques pour potentialiser l'immunité
WO2004092120A2 (fr) * 2003-04-07 2004-10-28 Nps Pharmaceuticals, Inc. Composes pyrimidinone en tant que calcilytiques
US20070161792A1 (en) * 2003-04-07 2007-07-12 Nps Pharmacueticals, Inc Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones
CN1835928A (zh) * 2003-04-07 2006-09-20 Nps制药公司 作为钙敏感受体拮抗剂的嘧啶酮化合物
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GEP20084342B (en) * 2003-05-22 2008-03-25 Composition comprising a pde4 inhibitor and a pde5 inhibitor
US7625909B2 (en) * 2003-05-23 2009-12-01 Novartis Vaccines And Diagnostics, Inc. Substituted quinazolinone compounds
JP2007501854A (ja) 2003-05-27 2007-02-01 ファイザー・プロダクツ・インク 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド［３，４−ｄ］ピリミジン類
CA2525383C (fr) 2003-06-06 2012-03-06 Arexis Ab Utilisation de composes heterocycliques comme inhibiteurs de l'enzyme chymotryptique de la couche cornee
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
JP2006527737A (ja) 2003-06-16 2006-12-07 アルタナ　ファルマ　アクチエンゲゼルシャフト 肺サーファクタントとｐｄｅ５阻害剤とを含有する肺疾病の治療用の組成物
WO2005002585A1 (fr) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combinaison d'un inhibiteur allosterique de la metalloproteinase-13 matricielle et d'un ligand au recepteur alpha-2-delta
AU2004255581A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
CA2531327A1 (fr) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. Composes et leur utilisation therapeutique
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
WO2005019190A2 (fr) * 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated Composes d'aminofurazan utiles comme inhibiteurs de proteine-kinases
WO2005020897A2 (fr) * 2003-08-22 2005-03-10 Dendreon Corporation Compositions et methodes permettant de traiter une maladie associee a l'expression de trp-p8
US20050059862A1 (en) * 2003-09-12 2005-03-17 Scimed Life Systems, Inc. Cannula with integrated imaging and optical capability
CN1882573A (zh) * 2003-09-16 2006-12-20 阿斯利康(瑞典)有限公司 作为酪氨酸激酶抑制剂的喹唑啉衍生物
US20050059851A1 (en) * 2003-09-17 2005-03-17 Vincent Ardizzone Flexible magnetic pad with multi-directional constantly alternating polarity zones
TW200524892A (en) 2003-09-24 2005-08-01 Glaxo Group Ltd Calcilytic compounds
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
MXPA06005736A (es) 2003-11-19 2006-12-14 Chiron Corp Compuestos de quinazolinona con bioacumulacion reducida.
NZ590160A (en) * 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
ES2371469T3 (es) 2003-12-01 2012-01-03 Kudos Pharmaceuticals Limited Inhibidores de reparación de daños en adn para el tratamiento del cáncer.
US20050136085A1 (en) * 2003-12-19 2005-06-23 David Bellamy Panthenol and natural organic extracts for reducing skin irritation
CN1898249A (zh) * 2003-12-19 2007-01-17 默克公司 有丝分裂驱动蛋白抑制剂
CA2549641A1 (fr) * 2003-12-19 2005-07-21 Merck & Co., Inc. Inhibiteurs mitotiques de la kinesine
CA2552664A1 (fr) 2004-01-08 2005-07-28 Michigan State University Methodes permettant de traiter et de prevenir l'hypertension et les troubles associes a l'hypertension
US20050227309A1 (en) 2004-01-21 2005-10-13 Corry Schuyler B Optically-detectable enzyme substrates and their method of use
RU2358969C2 (ru) 2004-02-13 2009-06-20 Баниу Фармасьютикал Ко., Лтд. Конденсированное 4-оксопиримидиновое производное
JP4838792B2 (ja) 2004-03-05 2011-12-14 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ５阻害剤のための新規の使用
JP2007530595A (ja) 2004-03-26 2007-11-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｅｒｋ２のピリジンインヒビターおよびそれらの使用
NZ551340A (en) 2004-04-22 2010-10-29 Boehringer Ingelheim Int Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder
EP1742924A4 (fr) * 2004-05-06 2010-10-06 Glaxosmithkline Llc Composes calcilytiques
CA2730540A1 (fr) * 2004-05-13 2005-12-01 Vanderbilt University Inhibiteurs selectifs de la phosphoinositide-3-kinase delta pour inhiber l'angiogenese
JP2008500338A (ja) * 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
KR20070038500A (ko) 2004-06-04 2007-04-10 아스트라제네카 아베 ｅｒｂＢ 수용체 타이로신 키나제로서의 퀴나졸린 유도체
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
TW200605430A (en) * 2004-07-20 2006-02-01 Avision Inc Electrical magnetic interference inspecting system
US7203079B2 (en) * 2004-07-23 2007-04-10 System General Corp. Switching controller having frequency hopping for power supplies
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
US7718658B2 (en) * 2004-09-02 2010-05-18 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
US8011027B2 (en) * 2004-11-17 2011-09-06 Interspiro, Inc. Protective seal mechanism
JP2006151028A (ja) * 2004-11-25 2006-06-15 Sumitomo Rubber Ind Ltd タイヤとリムとの組立体およびこれに用いるサポートリング
US7466645B2 (en) * 2004-12-21 2008-12-16 Panasonic Corporation OFDM signal receiving apparatus
US20070032506A1 (en) * 2005-07-02 2007-02-08 Peter Giannousis Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
RU2008130111A (ru) * 2005-12-22 2010-01-27 Алькон Рисерч, Лтд. (Us) (индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний
TWI338846B (en) * 2006-12-22 2011-03-11 Univ Nat Pingtung Sci & Tech A method for grid-based data clustering
EP1964548A1 (fr) 2007-03-02 2008-09-03 Novartis AG Compositions pharmaceutiques comprenant un agent calcilytique
CA2747417C (fr) * 2009-01-08 2017-01-03 Resverlogix Corp. Composes pour la prevention et le traitement de maladies cardiovasculaires

Also Published As

Publication number Publication date
US20080085887A1 (en) 2008-04-10
CL2007002864A1 (es) 2008-04-04
KR20090074066A (ko) 2009-07-03
US7829572B2 (en) 2010-11-09
MX2009003673A (es) 2009-04-22
PE20081455A1 (es) 2008-10-18
WO2008041118A2 (fr) 2008-04-10
CN101547922B (zh) 2012-06-20
UY30620A1 (es) 2008-05-31
AR063122A1 (es) 2008-12-30
JP2010505811A (ja) 2010-02-25
CN101547922A (zh) 2009-09-30
KR101129868B1 (ko) 2012-04-12
WO2008041118A3 (fr) 2008-10-23
IL197536A0 (en) 2009-12-24
TW200822929A (en) 2008-06-01
AU2007303846B2 (en) 2011-03-10
EP2079739A2 (fr) 2009-07-22
AU2007303846A1 (en) 2008-04-10
US20110028452A1 (en) 2011-02-03
NO20091328L (no) 2009-05-04
CA2663436A1 (fr) 2008-04-10

Similar Documents

Publication Publication Date Title
HK1137753A1 (en) Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
HRP20130660T1 (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
ZA200802588B (en) Imidazopyridine derivatives as A2B adenosine receptor antagonists
IL188725A0 (en) Pyrazine derivatives useful as adenosine receptor antagonists
ZA201004823B (en) Novel pyrazolo [3,4-d]pyrimidine derivatives as anti-cancer agents
HK1148521A1 (en) Pyrido[2,3-b]pyrazine-8-substituted compounds and their use [23-b]-8-
ME01952B (fr) 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidine-5-ones
ZA200810690B (en) Pyrido [2,3-B] pyrazine derivatives useful as herbicidal compounds
IL197243A0 (en) Pyrido (2,3-d)pyrimidinone compounds and their use as pi3 inhibitors
ZA201003050B (en) [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or pyridin-2-yle derivatives as protein kinase c-theta
IL188478A0 (en) Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
IL186881A (en) Pyrido derivatives [3,2– d] pyrimidine and their uses for the manufacture of drugs against hcv
EP2145887A4 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indole substitués et procédés de leur fabrication et utilisation
ZA201101701B (en) Pyrrolo[2,3-d]pyrimidine compounds
HK1126204A1 (en) Substituted bicyclic pyrimidone derivatives
EP2139333A4 (fr) Dérivés de pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine substituée en tant que modulateurs du récepteur de cannabinoïde-1
HUP0600858A2 (en) Piperizinyilpiperidine derivatives as chemokine receptor antagonists
EP2139332A4 (fr) Dérivés de pyrido[2,3-d]pyrimidine substitués en tant que modulateurs de récepteur de cannabinoïde-1
ZA201101861B (en) Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pyrimidines
IL210171A0 (en) Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2142542A4 (fr) Nouveaux composés d'imidazo [4,5-b] pyridine-7-carboxamides 704
ME01813B (me) Derivati pirido[2,3-d]pirimidina, njihovo dobijanje, njihova primjena u terapiji
PT1912976E (pt) Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a
ZA201105257B (en) 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyrimidine derivatives
IL188724A0 (en) NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160926